Carolina Rodrigues Tonon

Prof. Dr. Carolina Rodrigues Tonon

Botucatu Medical School - UNESP, Botucatu, São Paulo, Brazil
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2022 in Medical Science Monitor
Verified
Journal Article
Open access
CTCarolina Rodrigues Tonon
Carolina Rodrigues Tonon
TSTaline Alisson Artemis Lazzarin Silva
Taline Alisson Artemis Lazzarin Silva
FPFilipe Welson Leal Pereira
Filipe Welson Leal Pereira
DQDiego Aparecido Rios Queiroz
Diego Aparecido Rios Queiroz
EJEdson Luiz Favero Junior
Edson Luiz Favero Junior
BPBertha Furlan Polegato
Bertha Furlan Polegato
Calcium is the most abundant extracellular cation in the body, and it is responsible for structural and enzymatic functions. Calcium homeostasis is regulated by 3 factors: calcitonin, vitamin D, and parathyroid hormone (PTH). Hypercalcemia is defined by a serum calcium concentration >10.5 mg/dL, and it is classified into mild, moderate, and severe, depending on calcium values. Most cases are caused by primary hyperparathyroidism and malignancies. Various mechanisms are involved in the pathophysiology of hypercalcemia, such as excessive PTH production, production of parathyroid hormone-related protein (PTHrp), bone metastasis, extrarenal activation of vitamin D, and ectopic PTH secretion. The initial approach is similar in most cases, but a definitive treatment depends on etiology, that is why etiological investigation is mandatory in all cases. The majority of patients are asymptomatic and diagnosed during routine exams; only a small percentage of patients present with severe manifestations which can affect neurological, muscular, gastrointestinal, renal, and cardiovascular systems. Clinical manifestations are related to calcium levels, with higher values leading to more pronounced symptoms. Critically ill patients should receive treatment as soon as diagnosis is made. Initial treatment involves vigorous intravenous hydration and drugs to reduce bone resorption such as bisphosphonates and, more recently, denosumab, in refractory cases; also, corticosteroids and calcitonin can be used in specific cases. This review aims to provide a clinical update on current concepts of the pathophysiology of calcium homeostasis, epidemiology, screening, clinical presentation, diagnosis, and management of hypercalcemia.

29 December 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TLTaline Lazzarin
Taline Lazzarin
CTCarolina Rodrigues Tonon
Carolina Rodrigues Tonon
DMDanilo Martins
Danilo Martins
EJEdson Favero Junior
Edson Favero Junior
TBThiago Dias Baumgratz
Thiago Dias Baumgratz
MMMarcos Minicucci
Marcos Minicucci
Cardiac arrest is an important public health issue, with a survival rate of approximately 15 to 22%. A great proportion of these deaths occur after resuscitation due to post-cardiac arrest syndrome, which is characterized by the ischemia-reperfusion injury that affects the role body. Understanding physiopathology is mandatory to discover new treatment strategies and obtain better results. Besides improvements in cardiopulmonary resuscitation maneuvers, the great increase in survival rates observed in recent decades is due to new approaches to post-cardiac arrest care. In this review, we will discuss physiopathology, etiologies, and post-resuscitation care, emphasizing targeted temperature management, early coronary angiography, and rehabilitation.

Verified
Journal Article
Open access
PDF file
CTCarolina Rodrigues Tonon
Carolina Rodrigues Tonon
MMMarina Gaiato Monte
Marina Gaiato Monte
PBPaola Balin
Paola Balin
AFAnderson Seiji Fujimori
Anderson Seiji Fujimori
ARAna Paula D. Ribeiro
Ana Paula D. Ribeiro
BPBertha Furlan Polegato
Bertha Furlan Polegato
Doxorubicin is an effective drug for cancer treatment; however, cardiotoxicity limits its use. Cardiotoxicity pathophysiology is multifactorial. GLP-1 analogues have been shown to reduce oxidative stress and inflammation. In this study, we evaluated the effect of pretreatment with liraglutide on doxorubicin-induced acute cardiotoxicity. A total of 60 male Wistar rats were allocated into four groups: Control (C), Doxorubicin (D), Liraglutide (L), and Doxorubicin + Liraglutide (DL). L and DL received subcutaneous injection of liraglutide 0.6 mg/kg daily, while C and D received saline for 2 weeks. Afterwards, D and DL received a single intraperitoneal injection of doxorubicin 20 mg/kg; C and L received an injection of saline. Forty-eight hours after doxorubicin administration, the rats were subjected to echocardiogram, isolated heart functional study, and euthanasia. Liraglutide-treated rats ingested significantly less food and gained less body weight than animals that did not receive the drug. Rats lost weight after doxorubicin injection. At echocardiogram and isolated heart study, doxorubicin-treated rats had systolic and diastolic function impairment. Myocardial catalase activity was statistically higher in doxorubicin-treated rats. Myocardial protein expression of tumor necrosis factor alpha (TNF-α), phosphorylated nuclear factor-κB (p-NFκB), troponin T, and B-cell lymphoma 2 (Bcl-2) was significantly lower, and the total NFκB/p-NFκB ratio and TLR-4 higher in doxorubicin-treated rats. Myocardial expression of OPA-1, MFN-2, DRP-1, and topoisomerase 2β did not differ between groups (p > 0.05). In conclusion, doxorubicin-induced cardiotoxicity is accompanied by decreased Bcl-2 and phosphorylated NFκB and increased catalase activity and TLR-4 expression. Liraglutide failed to improve acute doxorubicin-induced cardiotoxicity in rats.

16 November 2023 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
LSLuiz Vicente Ribeiro Ferreira Silva-Filho
Luiz Vicente Ribeiro Ferreira Silva-Filho
RARodrigo Athanazio
Rodrigo Athanazio
CTCarolina Rodrigues Tonon
Carolina Rodrigues Tonon
JFJuliana CARVALHO FERREIRA
Juliana CARVALHO FERREIRA
SMSuzana Minamoto
Suzana Minamoto
Objective: To evaluate the effect of treatment with the combination of three cystic fibrosis transmembrane conductance regulator (CFTR) modulators-elexacaftor+tezacaftor+ivacaftor (ETI)-on important clinical endpoints in individuals with cystic fibrosis. Methods: This was a systematic review and meta-analysis of randomized clinical trials that compared the use of ETI in individuals with CF and at least one F508del allele with that of placebo or with an active comparator such as other combinations of CFTR modulators, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations and the Patients of interest, Intervention to be studied, Comparison of interventions, and Outcome of interest (PICO) methodology. We searched the following databases: MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov from their inception to December 26th, 2022. The risk of bias was assessed using the Cochrane risk-of-bias tool, and the quality of evidence was based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE). Results: We retrieved 54 studies in the primary search. Of these, 6 met the inclusion criteria and were analyzed (1,127 patients; 577 and 550 in the intervention and control groups, respectively). The meta-analysis revealed that the use of ETI increased FEV1% [risk difference (RD), +10.47%; 95% CI, 6.88-14.06], reduced the number of acute pulmonary exacerbations (RD, -0.16; 95% CI, -0.28 to -0.04), and improved quality of life (RD, +14.93; 95% CI, 9.98-19.89) and BMI (RD, +1.07 kg/m2; 95% CI, 0.90-1.25). Adverse events did not differ between groups (RD, -0.03; 95% CI, -0.08 to 0.01), and none of the studies reported deaths. Conclusions: Our findings demonstrate that ETI treatment substantially improves clinically significant, patient-centered outcomes.

20 October 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
TLTaline Lazzarin
Taline Lazzarin
LGLeonardo Rufino Garcia
Leonardo Rufino Garcia
DMDanilo Martins
Danilo Martins
DQDiego Queiroz
Diego Queiroz
CTCarolina Rodrigues Tonon
Carolina Rodrigues Tonon
Leonardo ZornoffLeonardo Zornoff
Leonardo Zornoff
Cardiac remodeling is defined as a group of molecular, cellular, and interstitial changes that manifest clinically as changes in the heart’s size, mass, geometry, and function after different injuries. Importantly, remodeling is associated with increased risk of ventricular dysfunction and heart failure. Therefore, strategies to attenuate this process are critical. Reactive oxygen species and oxidative stress play critical roles in remodeling. Importantly, antioxidative dietary compounds potentially have protective properties against remodeling. Therefore, this review evaluates the role of nutrients and food as modulators of cardiac remodeling.

10 August 2021 in American Journal of Case Reports
Verified
Journal Article
Open access
DMDanilo Martins
Danilo Martins
CTCarolina Rodrigues Tonon
Carolina Rodrigues Tonon
RPRafael Lopes Pacca
Rafael Lopes Pacca
NMNatanye Lemes Matchil
Natanye Lemes Matchil
LJLuiz Antonio Jorge Junior
Luiz Antonio Jorge Junior
MOMarina P Okoshi
Marina P Okoshi
Gout Storm - Article abstract #932683